Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.…
Fredag 10.00: Chatta med Marcus Hernhag
Biovica International (STO: BIOVIC-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 24 employees.
The shares were at 0.3000 SEK on 20 November 2026, down 49.0% over 52 weeks. Its 52-week range is 0.2700 SEK to 0.5960 SEK: the price is 49.7% below the high and 11.1% above the low.
Its market capitalisation is 116.76M SEK.
Biovica International reports return on equity of -80.9%, an operating margin of -479.1% and revenue up 55.8% year over year.
It holds more cash than debt, a net cash position of 45.56M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 0.6000 SEK is 100.0% above the current price.